Sharps Compliance (NASDAQ:SMED) Coverage Initiated at Robert W. Baird

Finally, Quantum Capital Management grew its stake in Sharps Compliance by 0.6% during the first quarter. Quantum Capital Management now owns …

Sharps Compliance Corp. logoRobert W. Baird initiated coverage on shares of Sharps Compliance (NASDAQ:SMED) in a research report report published on Wednesday, July 24th, Stock Target Advisor reports. The firm issued a buy rating and a $4.50 target price on the industrial products company’s stock.

A number of other research analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Sharps Compliance from a hold rating to a strong sell rating in a research report on Saturday, May 25th. Barrington Research restated a buy rating and set a $4.50 price objective on shares of Sharps Compliance in a research report on Tuesday, May 21st. Finally, Roth Capital initiated coverage on shares of Sharps Compliance in a research report on Wednesday, July 24th. They set a buy rating and a $4.50 price objective on the stock.

Shares of NASDAQ SMED opened at $3.62 on Wednesday. The business has a 50 day moving average price of $3.61. The company has a market capitalization of $58.44 million, a P/E ratio of -90.50, a PEG ratio of 1.62 and a beta of 0.24. Sharps Compliance has a 52-week low of $2.97 and a 52-week high of $4.22. The company has a current ratio of 2.49, a quick ratio of 1.95 and a debt-to-equity ratio of 0.04.

In other Sharps Compliance news, Director Parris H. Holmes, Jr. bought 40,000 shares of Sharps Compliance stock in a transaction on Thursday, June 13th. The stock was acquired at an average cost of $3.31 per share, with a total value of $132,400.00. Following the completion of the acquisition, the director now owns 942,027 shares in the company, valued at $3,118,109.37. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders have acquired 46,250 shares of company stock valued at $153,075. 20.70% of the stock is owned by corporate insiders.

Hedge funds have recently made changes to their positions in the business. Lapides Asset Management LLC increased its stake in shares of Sharps Compliance by 13.3% in the second quarter. Lapides Asset Management LLC now owns 164,700 shares of the industrial products company’s stock worth $586,000 after purchasing an additional 19,300 shares in the last quarter. Wells Fargo & Company MN grew its stake in Sharps Compliance by 8.3% during the second quarter. Wells Fargo & Company MN now owns 424,814 shares of the industrial products company’s stock valued at $1,512,000 after acquiring an additional 32,600 shares in the last quarter. Finally, Quantum Capital Management grew its stake in Sharps Compliance by 0.6% during the first quarter. Quantum Capital Management now owns 522,569 shares of the industrial products company’s stock valued at $1,913,000 after acquiring an additional 3,223 shares in the last quarter. 19.81% of the stock is owned by institutional investors and hedge funds.

About Sharps Compliance

Sharps Compliance Corp. provides medical, pharmaceutical, and hazardous waste management services in the United States. It offers Sharps Recovery System for the containment, transportation, treatment, and tracking of medical waste and used healthcare materials generated outside the hospital and health care facility settings; TakeAway Medication Recovery System, a solution that facilitates the proper disposal of unused medications; MedSafe, a solution for the safe collection, transportation, and proper disposal of unwanted and expired prescription medications; and ComplianceTRAC, a Web-based compliance and training program.

Recommended Story: What does a bar chart mean for investors?

Receive News & Ratings for Sharps Compliance Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sharps Compliance and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Direct Line Insurance Group PLC (LON:DLG) to Issue Dividend of GBX 7.20

Direct Line Insurance Group PLC (LON:DLG) announced a dividend on Wednesday, July 31st, Upcoming.Co.Uk reports. Investors of record on …

Direct Line Insurance Group logoDirect Line Insurance Group PLC (LON:DLG) announced a dividend on Wednesday, July 31st, Upcoming.Co.Uk reports. Investors of record on Thursday, August 8th will be given a dividend of GBX 7.20 ($0.09) per share on Friday, September 6th. This represents a dividend yield of 2.27%. The ex-dividend date of this dividend is Thursday, August 8th. The official announcement can be seen at this link.

Shares of LON:DLG opened at GBX 298.50 ($3.90) on Thursday. The stock has a 50-day simple moving average of GBX 329.40. The company has a current ratio of 1.49, a quick ratio of 0.93 and a debt-to-equity ratio of 16.68. Direct Line Insurance Group has a 12-month low of GBX 300.70 ($3.93) and a 12-month high of GBX 366.60 ($4.79). The firm has a market cap of $4.11 billion and a price-to-earnings ratio of 9.60.

DLG has been the topic of several research analyst reports. Shore Capital reaffirmed a “buy” rating on shares of Direct Line Insurance Group in a research note on Wednesday, July 31st. Berenberg Bank reduced their price objective on Direct Line Insurance Group from GBX 348 ($4.55) to GBX 344 ($4.49) and set a “hold” rating on the stock in a research note on Monday, July 15th. JPMorgan Chase & Co. reduced their price objective on Direct Line Insurance Group from GBX 360 ($4.70) to GBX 345 ($4.51) and set a “neutral” rating on the stock in a research note on Monday, July 8th. UBS Group reiterated a “buy” rating on shares of Direct Line Insurance Group in a report on Monday, July 29th. Finally, Peel Hunt reiterated an “add” rating and set a GBX 350 ($4.57) target price (up from GBX 345 ($4.51)) on shares of Direct Line Insurance Group in a report on Monday, July 29th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of GBX 361.08 ($4.72).

Direct Line Insurance Group Company Profile

Direct Line Insurance Group plc provides general insurance products and services in the United Kingdom. It operates through Motor, Home, Rescue and Other Personal Lines, and Commercial segments. The company offers personal motor, home, and rescue insurance products, as well as other personal line insurance products, including travel, pet, and creditor products; and commercial insurance for small and medium-sized enterprises.

Read More: What is the Book Value of a Share?

Dividend History for Direct Line Insurance Group (LON:DLG)

Receive News & Ratings for Direct Line Insurance Group Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Direct Line Insurance Group and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Ballentine Partners LLC Grows Stake in NVIDIA Co. (NASDAQ:NVDA)

Ballentine Partners LLC lifted its position in NVIDIA Co. (NASDAQ:NVDA) by 28.1% during the second quarter, HoldingsChannel.com reports.

NVIDIA logoBallentine Partners LLC lifted its position in NVIDIA Co. (NASDAQ:NVDA) by 28.1% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 3,608 shares of the computer hardware maker’s stock after purchasing an additional 792 shares during the period. Ballentine Partners LLC’s holdings in NVIDIA were worth $593,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in NVDA. Thor Advisors LLC purchased a new position in NVIDIA during the first quarter valued at $29,000. Harvest Group Wealth Management LLC purchased a new position in NVIDIA during the first quarter valued at $30,000. Truvestments Capital LLC purchased a new position in NVIDIA during the first quarter valued at $33,000. Field & Main Bank purchased a new position in NVIDIA during the second quarter valued at $33,000. Finally, Sound Income Strategies LLC lifted its position in NVIDIA by 96.2% during the second quarter. Sound Income Strategies LLC now owns 204 shares of the computer hardware maker’s stock valued at $34,000 after purchasing an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 67.47% of the company’s stock.

In other news, CFO Colette Kress sold 2,236 shares of NVIDIA stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $164.01, for a total value of $366,726.36. Following the sale, the chief financial officer now directly owns 239,710 shares of the company’s stock, valued at $39,314,837.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Harvey C. Jones sold 100,000 shares of NVIDIA stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $145.10, for a total value of $14,510,000.00. Following the completion of the sale, the director now directly owns 32,983 shares in the company, valued at $4,785,833.30. The disclosure for this sale can be found here. Insiders sold 104,736 shares of company stock worth $15,293,726 over the last ninety days. Insiders own 4.64% of the company’s stock.

Shares of NVDA stock opened at $152.35 on Wednesday. NVIDIA Co. has a 12-month low of $124.46 and a 12-month high of $292.76. The company has a quick ratio of 7.78, a current ratio of 8.98 and a debt-to-equity ratio of 0.25. The stock has a 50-day moving average price of $163.78. The company has a market capitalization of $92.78 billion, a PE ratio of 25.10, a price-to-earnings-growth ratio of 4.13 and a beta of 2.07.

NVIDIA (NASDAQ:NVDA) last issued its earnings results on Thursday, May 16th. The computer hardware maker reported $0.88 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.81 by $0.07. NVIDIA had a return on equity of 31.27% and a net margin of 30.68%. The firm had revenue of $2.22 billion for the quarter, compared to analysts’ expectations of $2.20 billion. During the same period in the previous year, the firm posted $2.05 earnings per share. The business’s revenue was down 30.8% compared to the same quarter last year. As a group, research analysts forecast that NVIDIA Co. will post 4.16 EPS for the current fiscal year.

Several equities analysts recently weighed in on the company. Barclays lowered their target price on NVIDIA from $220.00 to $180.00 and set an “overweight” rating on the stock in a research report on Thursday, June 6th. Royal Bank of Canada lifted their target price on NVIDIA to $200.00 and gave the company an “outperform” rating in a research report on Monday, May 13th. Summit Redstone downgraded NVIDIA to a “hold” rating in a research report on Friday, May 17th. Cascend Securities upgraded NVIDIA from a “hold” rating to a “buy” rating and set a $190.00 target price on the stock in a research report on Thursday, July 11th. Finally, Summit Insights downgraded NVIDIA from a “buy” rating to a “hold” rating and set a $158.57 target price on the stock. in a research report on Friday, May 17th. Three equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and twenty-six have issued a buy rating to the company. NVIDIA presently has a consensus rating of “Buy” and an average price target of $194.34.

NVIDIA Company Profile

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the Graphics Processing Unit (GPU) and Tegra Processor segments. The GPU segment comprises of product brands which aims specialized markets including GeForce for gamers; Quadro for designers; Tesla and DGX for AI data scientists and big data researchers; and GRID for cloud-based visual computing users.

Further Reading: How are institutional investors different from individual investors?

Want to see what other hedge funds are holding NVDA?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NVIDIA Co. (NASDAQ:NVDA).

Institutional Ownership by Quarter for NVIDIA (NASDAQ:NVDA)

Receive News & Ratings for NVIDIA Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NVIDIA and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

FNY Investment Advisers LLC Makes New $70000 Investment in Silk Road Medical Inc (NASDAQ …

Separately, Norwest Venture Partners Xiii LP acquired a new stake in Silk Road Medical during the 2nd quarter worth about $119,307,000. 8.04% of …

Silk Road Medical logoFNY Investment Advisers LLC acquired a new position in shares of Silk Road Medical Inc (NASDAQ:SILK) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,458 shares of the company’s stock, valued at approximately $70,000.

Separately, Norwest Venture Partners Xiii LP acquired a new stake in Silk Road Medical during the 2nd quarter worth about $119,307,000. 8.04% of the stock is currently owned by institutional investors and hedge funds.

Shares of Silk Road Medical stock opened at $39.35 on Tuesday. Silk Road Medical Inc has a 52-week low of $30.87 and a 52-week high of $51.50. The firm’s 50-day moving average price is $43.78.

Silk Road Medical (NASDAQ:SILK) last announced its quarterly earnings results on Monday, July 29th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.14). The firm had revenue of $14.93 million during the quarter, compared to analyst estimates of $13.64 million. Silk Road Medical’s revenue for the quarter was up 92.2% compared to the same quarter last year. Sell-side analysts anticipate that Silk Road Medical Inc will post -2.02 earnings per share for the current year.

A number of equities research analysts have commented on SILK shares. JPMorgan Chase & Co. started coverage on Silk Road Medical in a research report on Monday, April 29th. They set an “overweight” rating and a $45.00 price objective for the company. Bank of America assumed coverage on Silk Road Medical in a research report on Monday, April 29th. They set a “neutral” rating and a $43.00 price objective for the company. They noted that the move was a valuation call. Stifel Nicolaus assumed coverage on Silk Road Medical in a report on Monday, April 29th. They set a “buy” rating and a $44.00 price target for the company. Zacks Investment Research lowered Silk Road Medical from a “buy” rating to a “hold” rating in a report on Friday. Finally, BMO Capital Markets assumed coverage on Silk Road Medical in a report on Monday, April 29th. They set an “outperform” rating and a $40.01 price target for the company. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $43.60.

About Silk Road Medical

Silk Road Medical, Inc operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices.

Featured Story: What is the Quick Ratio?

Institutional Ownership by Quarter for Silk Road Medical (NASDAQ:SILK)

Receive News & Ratings for Silk Road Medical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Silk Road Medical and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Edge Wealth Management LLC Grows Stake in BGC Partners, Inc. (NASDAQ:BGCP)

Norges Bank purchased a new position in BGC Partners in the fourth quarter valued at about $14,373,000. Millennium Management LLC boosted its …

BGC Partners logoEdge Wealth Management LLC increased its position in shares of BGC Partners, Inc. (NASDAQ:BGCP) by 190.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,505 shares of the financial services provider’s stock after buying an additional 9,505 shares during the period. Edge Wealth Management LLC’s holdings in BGC Partners were worth $76,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Norges Bank purchased a new position in BGC Partners in the fourth quarter valued at about $14,373,000. Millennium Management LLC boosted its holdings in BGC Partners by 195.8% in the fourth quarter. Millennium Management LLC now owns 2,961,665 shares of the financial services provider’s stock worth $15,312,000 after acquiring an additional 1,960,414 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in BGC Partners by 8.3% in the first quarter. Principal Financial Group Inc. now owns 18,685,542 shares of the financial services provider’s stock worth $99,223,000 after acquiring an additional 1,436,046 shares in the last quarter. Raymond James & Associates lifted its holdings in shares of BGC Partners by 12.2% during the first quarter. Raymond James & Associates now owns 11,229,356 shares of the financial services provider’s stock worth $59,628,000 after purchasing an additional 1,224,232 shares during the period. Finally, First Trust Advisors LP acquired a new stake in shares of BGC Partners during the first quarter worth about $6,086,000. Hedge funds and other institutional investors own 51.52% of the company’s stock.

BGCP stock traded up $0.02 during trading on Tuesday, hitting $5.09. 55,067 shares of the company traded hands, compared to its average volume of 1,749,734. The firm has a market capitalization of $1.72 billion, a P/E ratio of 7.05 and a beta of 1.39. BGC Partners, Inc. has a 1 year low of $4.46 and a 1 year high of $12.65. The stock’s 50-day moving average is $5.38. The company has a current ratio of 1.11, a quick ratio of 1.09 and a debt-to-equity ratio of 1.15.

BGC Partners (NASDAQ:BGCP) last posted its quarterly earnings data on Thursday, July 25th. The financial services provider reported $0.17 EPS for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.01). The business had revenue of $551.20 million during the quarter, compared to analysts’ expectations of $546.65 million. BGC Partners had a net margin of 6.98% and a return on equity of 35.34%. The firm’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.30 earnings per share. Research analysts predict that BGC Partners, Inc. will post 0.63 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 28th. Investors of record on Wednesday, August 14th will be given a dividend of $0.14 per share. This represents a $0.56 annualized dividend and a dividend yield of 11.00%. The ex-dividend date is Tuesday, August 13th. BGC Partners’s payout ratio is 77.78%.

A number of research firms recently commented on BGCP. Zacks Investment Research downgraded BGC Partners from a “hold” rating to a “sell” rating in a report on Monday. BidaskClub raised BGC Partners from a “hold” rating to a “buy” rating in a report on Saturday, July 6th. Two research analysts have rated the stock with a sell rating, one has assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $11.00.

BGC Partners Company Profile

BGC Partners, Inc operates as a brokerage and financial technology company worldwide. It offers various brokerage products, such as fixed income, foreign exchange, equities, energy and commodities, insurance, and futures. The company also provides other services that include trade execution, broker dealer, clearing, trade compression, post-trade, information, and other back office services to financial and non-financial institutions.

Featured Article: Resistance Level

Institutional Ownership by Quarter for BGC Partners (NASDAQ:BGCP)

Receive News & Ratings for BGC Partners Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BGC Partners and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts